AAAAAA
Results:
1-7
|
Results: 7
Authors:
Labrie, F
Candas, B
Cusan, L
Gomez, JL
Citation: F. Labrie et al., The Laval University screening trial results, CURR CLIN U, 2001, pp. 255-279
Authors:
Candas, B
Cusan, L
Gomez, JL
Diamond, P
Suburu, RE
Levesque, J
Brousseau, G
Belanger, A
Labrie, F
Citation: B. Candas et al., Evaluation of prostatic specific antigen and digital rectal examination asscreening tests for prostate cancer, PROSTATE, 45(1), 2000, pp. 19-35
Authors:
Labrie, F
Cusan, L
Gomez, JL
Belanger, A
Candas, B
Citation: F. Labrie et al., Long-term combined androgen blockade alone for localized prostate cancer, MOL UROL, 3(3), 1999, pp. 217-225
Authors:
Labrie, F
Labrie, C
Belanger, A
Simard, J
Gauthier, S
Luu-The, V
Merand, Y
Giguere, V
Candas, B
Luo, SQ
Martel, C
Singh, SM
Fournier, M
Coquet, A
Richard, V
Charbonneau, R
Charpenet, G
Tremblay, A
Tremblay, G
Cusan, L
Veilleux, R
Citation: F. Labrie et al., EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen inthe mammary gland and endometrium, J STEROID B, 69(1-6), 1999, pp. 51-84
Authors:
Labrie, F
Candas, B
Dupont, A
Cusan, L
Gomez, JL
Suburu, RE
Diamond, P
Levesque, J
Belanger, A
Citation: F. Labrie et al., Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial, PROSTATE, 38(2), 1999, pp. 83-91
Authors:
van der Kwast, TH
Tetu, B
Candas, B
Gomez, JL
Cusan, L
Labrie, F
Citation: Th. Van Der Kwast et al., Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: Three versus six months of endocrine therapy, UROLOGY, 53(3), 1999, pp. 523-529
Authors:
Tetu, B
Van der Kwast, TH
Fradet, Y
Candas, B
Gomez, JL
Cusan, L
Labrie, F
Citation: B. Tetu et al., Morphologic effects of neoadjuvant hormone therapy on prostate cancer, MOL UROL, 2(3), 1998, pp. 103-107
Risultati:
1-7
|